Category Business

Nutriband Secures U.S. Patent Approval for Aversa™ Transdermal Abuse Deterrent Technology

Nutriband Secures U.S. Patent Approval for Aversa™ Transdermal Abuse Deterrent Technology Nutriband a pharmaceutical company specializing in the development of prescription transdermal products, recently announced that it has received a Notice of Allowance from the United States Patent and Trademark…

Read MoreNutriband Secures U.S. Patent Approval for Aversa™ Transdermal Abuse Deterrent Technology
Miist Therapeutics

Medications from Miist Therapeutics Secures $7M in Funding to Develop Fast-Acting Treatments

Medications from Miist Therapeutics Secures $7M in Funding to Develop Fast-Acting Treatments Medications Miist Therapeutics, a trailblazing company focused on the development of physics-based inhaled medicines, has announced that it has secured $7 million in seed funding from a group…

Read MoreMedications from Miist Therapeutics Secures $7M in Funding to Develop Fast-Acting Treatments
Pharmaceuticals

Tonix Pharmaceuticals Appoints Siobhan Fogarty as Chief Technical Officer

Tonix Pharmaceuticals Appoints Siobhan Fogarty as Chief Technical Officer Tonix Pharmaceuticals Holding a fully integrated biopharmaceutical company specializing in the development and commercialization of innovative therapies for pain management and other health challenges, has announced the promotion of Siobhan Fogarty…

Read MoreTonix Pharmaceuticals Appoints Siobhan Fogarty as Chief Technical Officer
AdvanCell

AdvanCell Closes Oversubscribed $112M Series C Funding

AdvanCell Closes Oversubscribed $112M Series C Funding AdvanCell, a pioneering clinical-stage radiopharmaceutical company focused on developing groundbreaking cancer therapeutics, has announced the successful closure of an oversubscribed US$112 million Series C financing round. This significant milestone highlights the confidence investors…

Read MoreAdvanCell Closes Oversubscribed $112M Series C Funding
Cystic Fibrosis

Cystic Fibrosis Biotech Sionna Announces Groundbreaking $150M IPO for Treatment Development

Sionna Therapeutics Announces $150M IPO to Advance Cystic Fibrosis Drug Development Sionna Therapeutics, a Massachusetts-based biotechnology company specializing in cystic fibrosis (CF) treatments, has officially announced the terms of its highly anticipated initial public offering (IPO). The company aims to…

Read MoreCystic Fibrosis Biotech Sionna Announces Groundbreaking $150M IPO for Treatment Development

IMCAS 2025: Galderma Phase IIIb Data Show Rapid, Long-Lasting Benefits of Relfydess™

Galderma’s Breakthrough Findings Galderma (SWX:GALD), a global leader in dermatology, has announced the results of its Phase IIIb RELAX clinical trial, demonstrating the rapid onset, long-lasting efficacy, and high patient satisfaction of RelabotulinumtoxinA (Relfydess™) for treating frown lines (glabellar lines).…

Read MoreIMCAS 2025: Galderma Phase IIIb Data Show Rapid, Long-Lasting Benefits of Relfydess™